4.1 Article

Evidence for generalizability of edaravone efficacy using a novel machine learning risk-based subgroup analysis tool

Related references

Note: Only part of the references are listed.
Article Clinical Neurology

Post-hoc analyses of the edaravone clinical trials Study 16 and Study 19: a step toward more efficient clinical trial designs in amyotrophic lateral sclerosis

Joseph M. Palumbo et al.

AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEGENERATION (2019)

Article Clinical Neurology

Refining eligibility criteria for amyotrophic lateral sclerosis clinical trials

Ruben P. A. van Eijk et al.

NEUROLOGY (2019)

Review Medicine, General & Internal

Amyotrophic Lateral Sclerosis: An Update for 2018

Bjorn Oskarsson et al.

MAYO CLINIC PROCEEDINGS (2018)

Article Clinical Neurology

A post-hoc subgroup analysis of outcomes in the first phase III clinical study of edaravone (MCI-186) in amyotrophic lateral sclerosis

Koji Abe et al.

AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEGENERATION (2017)

Article Clinical Neurology

A randomized, placebo-controlled, double-blind phase IIb trial evaluating the safety and efficacy of tirasemtiv in patients with amyotrophic lateral sclerosis

Jeremy M. Shefner et al.

AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEGENERATION (2016)

Article Medicine, General & Internal

Amyotrophic lateral sclerosis

Matthew C. Kiernan et al.

LANCET (2011)